Foreground: Androgenic alopecia (pattern alopecia), which affects both men and women, is a highly prevalent condition. In general, men are thought to have a higher incidence of androgenetic alopecia than women, however some data shows that the apparent disparities in frequency may be due to different expression in men and women. Vaspin is an adipokine that reduces inflammation. Vaspin-expressing cells are mostly keratinocytes. VASPIN modulated keratinocyte-immune cell communication and decreased the inflammatory cell production of cytokines and chemokines. Vaspin serum levels in individuals with androgenetic alopecia were evaluated in this research and its clinical importance was assessed. We used case-control design for this research. Fifty AGA patients were studied, with a control group of 30 people who seemed to be healthy but were the same age and gender as the AGA patients (Group B). In the outpatient clinic of Benha University Hospitals' Dermatology and Andrology department, patients were re-referred. Results: We found no significant differences in age, gender, or BMI between the patients and the controls in our research. The start and progression of our patients' illnesses are gradual. The average number of years that patients were sick was 9.5 years. Systemic illnesses were not present, and 82% of patients had favourable family histories; 66% of patients had had therapy for AGA. Patients with androgenetic alopecia had considerably lower serum vaspin levels than healthy controls. There were no significant associations between the Vaspin level and age, sex or smoking or BMI or duration or grading or treatment or family history or part width or acne, scalp skin, or body hair of any kind. This study found that the serum level of vaspin (AUC=0.664) had a reasonable AUC. There was an 87.5 percent negative predictive value (NPV) at the cutoff value of 2302.2 pounds per deciliter (pigs/dl). As a result, Vaspin deficiency may be utilised to detect androgenic alopecia at an early stage in the disease's progression.